https://www.stellarmr.com/report/ozempic-market/2744 The Ozempic (semaglutide) market remarkable expansion is fueled by Ozempic dual approval for type 2 diabetes management and more recently, chronic weight management, positioning it as blockbuster therapy in GLP-1 receptor agonist class. Novo Nordisk's flagship product now commands 62% of anti-diabetic injectables market while its off-label use for obesity accounts for 38% of total prescriptions (CDC, 2025), despite ongoing regulatory scrutiny of this application.